Novavax (NVAX) Current Leases (2012 - 2026)

Novavax's Current Leases history runs 10 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Current Leases fell 61.45% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 61.45% decrease from a year earlier, with the FY2025 full-year figure at $2.5 million, down 64.23% from the prior year.
• Current Leases eased to $2.1 million in Q1 2026 per NVAX's latest filing, from $2.5 million in the prior quarter.
• Across five years, Current Leases topped out at $124.3 million in Q2 2022 and bottomed at $953000.0 in Q2 2023.
• The 5-year median for Current Leases is $5.6 million (2025), against an average of $25.2 million.
• Across the five-year window, Current Leases plunged 99.23% in 2023 and surged 889.19% in 2024, its largest moves.
• Year by year, Current Leases stood at $44.1 million in 2022, then plunged by 88.33% to $5.1 million in 2023, then surged by 36.31% to $7.0 million in 2024, then slumped by 64.23% to $2.5 million in 2025, then dropped by 15.76% to $2.1 million in 2026.
• Per Business Quant, the three latest NVAX Current Leases figures stand at $2.1 million (Q1 2026), $2.5 million (Q4 2025), and $5.0 million (Q3 2025).